Birgi Mefar Group
Birgi Mefar Group is a privately held Turkish pharmaceutical CDMO founded in 1963 that manufactures type-1 tubular glass ampoules and vials and provides contract sterile injectable fill-finish services to 60+ global pharmaceutical companies across 150+ APIs.
- Company typePrivate
- Founded1963
- HeadquartersIstanbul
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What Birgi Mefar Group does
Birgi Mefar Group is a privately held, family-owned Turkish pharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 1963 by Adnan Birgi, headquartered in Istanbul with two operational subsidiaries: Birgi Sanayi A.Ş. (primary glass packaging manufacturer) and Mefar İlaç Sanayi (sterile injectable manufacturer). The group manufactures type-1 tubular glass ampoules and vials in sizes from 1 ml to 30 ml (clear and amber variants) and provides contract sterile fill-finish services across ampoules, vials, lyophilized vials, pre-filled syringes (PFS), and Blow-Fill-Seal (BFS) formats, supported by in-house R&D, laboratory services, serialization, cold chain management, and warehousing/logistics.
The company serves over 60 global and local pharmaceutical customers across 150+ different active pharmaceutical ingredients (APIs), with 40%+ of revenue derived from international markets. It holds FDA-DMF Type III filings for primary packaging products targeting the US market, Health Canada-DMF Type II filings for Canadian market access, and received EU GMP certification in December 2025 enabling broader European pharmaceutical contract manufacturing. Manufacturing operations span a 17,500 m2 closed-area sterile facility in Kurtköy, Pendik and a glass packaging facility in Samandıra, employing 650+ dedicated staff under a CXO leadership team including a CFO, CTO/Qualified Person, COO, and Chief Business Development Officer.
The business model is contract fee-based B2B sales to licensed pharmaceutical companies, with quote-based pricing rather than publicly disclosed rates. Revenue is generated through manufacturing service fees for sterile injectable production, primary packaging material sales, and ancillary services including packaging, serialization, and cold chain logistics. The go-to-market motion is sales-led and direct, targeting enterprise pharmaceutical clients through industry events, LinkedIn presence, and company website channels.
Birgi Mefar Group firmographics
Firmographics- Name
- Birgi Mefar Group
- Legal name
- Birgi Mefar Group
- Website
- https://mefar.com
- Company type
- Private
- Founded year
- 1963
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Birgi Mefar Group is a privately held Turkish pharmaceutical CDMO founded in 1963 that manufactures type-1 tubular glass ampoules and vials and provides contract sterile injectable fill-finish services to 60+ global pharmaceutical companies across 150+ APIs.
- Ownership category
- akta.pro rank
Birgi Mefar Group industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
- akta.pro secondary industries
- Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes) (IMALAEAB), Small-Molecule API & Intermediates CDMO (HLAGABAA), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where Birgi Mefar Group is headquartered
LocationHeadquarters
- HQ city
- Istanbul
Offices2 records
Markets served
Birgi Mefar Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Contract Manufacturing Services: Provides sterile pharmaceutical manufacturing services as a CDMO (Contract Development and Manufacturing Organization) to pharmaceutical companies. Revenue generated through manufacturing fees for sterile injectable products, primary packaging materials, and related services.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Birgi Mefar Group product offering
Product offeringCore offering
Birgi Mefar Group operates as a Contract Development and Manufacturing Organization (CDMO) providing sterile injectable pharmaceutical manufacturing services through its subsidiary Mefar İlaç Sanayi, covering ampoules, vials, lyophilized vials, pre-filled syringes and Blow-Fill-Seal aseptic production, together with laboratory, packaging, serialization, cold-chain management and warehousing services. Its subsidiary Birgi Sanayi A.Ş. manufactures primary pharmaceutical packaging (empty type-1 tubular glass ampoules and vials from 1 ml to 30 ml in clear and amber variants) supplied as primary packaging material to pharmaceutical customers globally.
Product overview
Birgi Mefar Group operates as a Contract Development and Manufacturing Organization (CDMO) providing integrated pharmaceutical manufacturing services. The portfolio comprises three main areas: (1) Primary glass packaging manufacturing through Birgi Sanayi A.Ş., producing empty ampoules and vials from type-1 tubular glass; (2) Sterile injectable pharmaceutical manufacturing services through Mefar İlaç Sanayi, including ampoules, vials, lyo vials, pre-filled syringes, and blow-fill-seal technology; and (3) Comprehensive support services including laboratory services, packaging, serialization, cold chain management, and warehousing & logistics. The company serves over 50 global and local pharmaceutical customers with more than 150 different raw materials.
Differentiator
Problem solved
Functional benefit
Products and services
- Empty Ampoules Empty ampoules manufactured from type-1 tubular glass in sizes ranging from 1 ml to 30 ml, available in clear and amber glass variants, produced in accordance with ISO, DIN, AFNOR, BS or other specified standards. Supplied to pharmaceutical companies as primary packaging material, with FDA-DMF Type III numbers 19065 (clear) and 19066 (amber) and Health Canada-DMF Type II 2014-184.
- Empty Vials Empty vials manufactured from type-1 tubular glass in sizes ranging from 1 ml to 30 ml, available in clear and amber glass variants, packaged in clean-room conditions in fiber-free cartons or PVC boxes. Supplied to pharmaceutical companies as primary packaging material, with FDA-DMF Type III numbers 19067 (clear) and 19068 (amber).
- Ampoules (Sterile Injectable) Sterile injectable pharmaceutical contract manufacturing service for ampoule products, provided by Mefar İlaç Sanayi to licensed pharmaceutical customers.
- Vials (Sterile Injectable) Sterile injectable pharmaceutical contract manufacturing service for vial products, provided by Mefar İlaç Sanayi to licensed pharmaceutical customers.
- Lyo Vials (Sterile Injectable) Lyophilized (freeze-dried) vial sterile injectable pharmaceutical contract manufacturing service, provided by Mefar İlaç Sanayi to licensed pharmaceutical customers.
- Pre-Filled Syringes (PFS) Sterile injectable pharmaceutical contract manufacturing service for pre-filled syringe products, provided by Mefar İlaç Sanayi to licensed pharmaceutical customers.
- Blow-Fill-Seal (BFS) Advanced aseptic manufacturing technology using Blow-Fill-Seal (BFS) process for sterile pharmaceutical products, provided by Mefar İlaç Sanayi to licensed pharmaceutical customers.
- Cold Chain Management Temperature-controlled storage and logistics management for temperature-sensitive pharmaceutical products requiring specific handling conditions, supporting the group's sterile injectable manufacturing customers.
- Warehousing & Logistics Comprehensive warehousing and logistics services including stock quarantine, release management, labelling, packaging, and serialization for pharmaceutical customers.
Companies that use Birgi Mefar Group
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles1 record
Birgi Mefar Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Birgi Mefar Group partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ArceraminorBirgi Mefar Group announced partnership involvement with Arcera as part of an appointment announcement. Arcera appears to be a strategic partner in the pharmaceutical/biopharmaceutical sector.
Scale indicators5 records
Recent moves4 records
Expansion highlights5 records
Birgi Mefar Group competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights6 records
Customer concentration
Birgi Mefar Group social profiles
Digital presenceBirgi Mefar Group compliance and trust
Trust signalCompliance4 records
Birgi Mefar Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Birgi Mefar Group leadership team
Management profileNumber of profiles
Profiles9 records
Birgi Mefar Group subsidiaries and ownership
Company hierarchySubsidiaries2 records
Birgi Mefar Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Birgi Mefar Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Birgi Mefar Group
What does Birgi Mefar Group do?
Birgi Mefar Group operates as a Contract Development and Manufacturing Organization (CDMO) providing sterile injectable pharmaceutical manufacturing services through its subsidiary Mefar İlaç Sanayi, covering ampoules, vials, lyophilized vials, pre-filled syringes and Blow-Fill-Seal aseptic production, together with laboratory, packaging, serialization, cold-chain management and warehousing services. Its subsidiary Birgi Sanayi A.Ş. manufactures primary pharmaceutical packaging (empty type-1 tubular glass ampoules and vials from 1 ml to 30 ml in clear and amber variants) supplied as primary packaging material to pharmaceutical customers globally.
Is Birgi Mefar Group a public or private company?
Birgi Mefar Group is a private company. It is classified as family owned and is currently operating.
When was Birgi Mefar Group founded?
Birgi Mefar Group was founded in 1963. It employs 501 to 1,000 people.
Where is Birgi Mefar Group based?
Birgi Mefar Group is headquartered in Istanbul.
How does Birgi Mefar Group make money?
One revenue line is on record: contract Manufacturing Services.
Does Birgi Mefar Group have an API?
No public API is recorded for Birgi Mefar Group.
What industry is Birgi Mefar Group in?
Birgi Mefar Group's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of IMALAEAB, Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes). Its NAICS code is 325412 and its SIC code is 2834.